Zolgensma® (onasemnogene abeparvovec-xioi) a new drug approved by the FDA , costs more than $2.1 million. Zolgensma® is a gene replacement therapy indicated for the treatment of spinal muscular atrophy (SMA) in paediatric patients. Originally developed by Avexis, the drug became a part of Novartis’ portfolio after it acquired Avexis in May 2018. Zolgensma can be a one-time, life-saving treatment that allows for children with SMA to function in ways unimaginable just a few years ago.
Reuters
